摘要:
A synthesis approach providing an early ring attachment via a bromination to compound 1-1 yielding compound II-II whereby a final product such as AA can be synthesized. In particular, the 2,4-difluorophenyl-containing sidechain is attached before creation of the additional ring Q.
摘要:
Is to provide a novel compound having an anti-viral activity, particularly a HIV integrase inhibitory activity, and an agent, particularly an anti-HIV agent.A compound represented by the formula: (wherein Z1 is NR4 (R4 is hydrogen, optionally substituted lower alkyl etc.), O or CH2; Z2 is optionally substituted lower alkylene or optionally substituted lower alkenylene, each may be intervened by a heteroatom group selected from group consisting O, S, SO, SO2, NR5 (R5 is selected independently from the same substituent group of R4) —N═ and ═N—; R1 is hydrogen or lower alkyl; X is a single bond, a heteroatom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylene each may be intervened by the heteroatom group; R2 is optionally substituted aryl; R3 is hydrogen, halogen, hydroxy, optionally substituted alkyl group etc.)
摘要翻译:是提供具有抗病毒活性,特别是HIV整合酶抑制活性的新型化合物和药剂,特别是抗HIV剂。 由下式表示的化合物(其中Z 1为NR 4(R 4为氢,任选取代的低级烷基等),O或CH 2; Z 2为任选取代的低级亚烷基或任选取代的低级亚烯基,各自可以被选自 来自由O,S,SO,SO 2,NR 5组成的基团(R 5独立地选自与R 4相同的取代基组)-N =和N - ; R 1是氢或低级烷基; X是单键, O,S,SO,SO 2和NH,或低级亚烷基或低级亚烯基各自可以被杂原子基团插入; R2是任选取代的芳基; R 3是氢,卤素,羟基,任选取代的烷基等)
摘要:
A synthesis approach providing an early ring attachment via a bromination to compound I-I yielding compound II-II: whereby a final product such as AA: can be synthesized. In particular, the 2,4-difluorophenyl-containing sidechain is attached before creation of the additional ring Q.
摘要:
[Object] Is to provide a novel compound having an anti-viral activity, particularly a HIV integrase inhibitory activity, and an agent, particularly an anti-HIV agent. [Solving means] A compound represented by the formula: (wherein Z1 is NR4 (R4 is hydrogen, optionally substituted lower alkyl etc.), O or CH2; Z2 is optionally substituted lower alkylene or optionally substituted lower alkenylene, each may be intervened by a heteroatom group selected from group consisting O, S, SO, SO2, NR5 (R5 is selected independently from the same substituent group of R4)—N═ and ═N—; R1 is hydrogen or lower alkyl; X is a single bond, a heteroatom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylene each may be intervened by the heteroatom group; R2 is optionally substituted aryl; R3 is hydrogen, halogen, hydroxy, optionally substituted alkyl group etc.)
摘要翻译:本发明提供具有抗病毒活性,特别是HIV整合酶抑制活性的新型化合物和药剂,特别是抗HIV剂。 [解决方案]由下式表示的化合物(其中Z 1是NR 4)(R 4)是氢,任选取代的低级烷基等 。),O或CH 2; Z 2是任选取代的低级亚烷基或任选取代的低级亚烯基,各自可以被选自O,S SO,SO 2,NR 5(R 5)独立地选自与R 4相同的取代基, )-N-和-N-; R 1是氢或低级烷基; X是单键,选自O,S,SO,SO 2的杂原子基团; 和NH,或低级亚烷基或低级亚烯基各自可以被杂原子基团插入; R 2是任选取代的芳基; R 3是氢,卤素,羟基,任选取代的 烷基等)
摘要:
Is to provide a novel compound having an anti-viral activity, particularly a HIV integrase inhibitory activity, and a pharmaceutical composition, particularly an anti-HIV agent. (wherein R1 is hydrogen or lower alkyl; X is lower alkylene etc.; R2 is optionally substituted aryl; R3 is hydrogen, halogen, hydroxy, optionally substituted lower alkyl etc.; R4 is hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl lower alkyl, optionally substituted aryl, optionally substituted aryl lower alkyl, optionally substituted heterocyclic group, optionally substituted heterocyclic lower alkyl etc.; A broken line indicates the presence or absence of a bond; B1 and B2 are such that any one of them is CR20R21, and the other is NR22 and, in this case, there is no broken line. When B2 is NR22, R4 and R22 may be connected together to form an optionally substituted heterocycle;When B2 is CHR21, R4 and R21 may be connected together to form an optionally substituted heterocycle.Alternatively, B1 and B2 are independently C, CR23 or N and, in this case, B1 and B2 may be taken together to form a heterocycle.R20, R21, R22 and R23 are independently hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl lower alkyl etc.)
摘要:
Is to provide a novel compound having an anti-viral activity, particularly a HIV integrase inhibitory activity, and a pharmaceutical composition, particularly an anti-HIV agent. (wherein R1 is hydrogen or lower alkyl; X is lower alkylene etc.; R2 is optionally substituted aryl; R3 is hydrogen, halogen, hydroxy, optionally substituted lower alkyl etc.; R4 is hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl lower alkyl, optionally substituted aryl, optionally substituted aryl lower alkyl, optionally substituted heterocyclic group, optionally substituted heterocyclic lower alkyl etc.; A broken line indicates the presence or absence of a bond; B1 and B2 are such that any one of them is CR20R21, and the other is NR22 and, in this case, there is no broken line. When B2 is NR22, R4 and R22 may be connected together to form an optionally substituted heterocycle;When B2 is CHR21, R4 and R21 may be connected together to form an optionally substituted heterocycle.Alternatively, B1 and B2 are independently C, CR23 or N and, in this case, B1 and B2 may be taken together to form a heterocycle.R20, R21, R22 and R23 are independently hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl lower alkyl etc.)
摘要:
The present invention is to provide a novel compound (I) shown below, having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. (wherein Z1 is NR4; R1 is hydrogen or lower alkyl; X is a single bond, a hetero atom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylene in which the hetero atom group may intervene; R2 is optionally substituted aryl; R3 is hydrogen, a halogen, hydroxy, optionally substituted lower alkyl etc; and R4 and Z2 part taken together forms a ring, to form a polycyclic compound, including e.g., a tricyclic or tetracyclic compound.
摘要翻译:本发明提供下述新型化合物(I),具有抗病毒活性,特别是HIV整合酶抑制活性,以及含有该化合物(I)的药物,特别是抗HIV药物,以及方法和 中间体。 (其中Z 1为NR 4; R 1为氢或低级烷基; X为单键,选自O,S,SO,SO 2和NH的杂原子基团,或杂原子基团可插入的低级亚烷基或低级亚烯基) R2是任选取代的芳基; R 3是氢,卤素,羟基,任选取代的低级烷基等;和R 4和Z 2部分一起形成环,形成多环化合物,包括例如三环或四环化合物。
摘要:
The present invention is directed to a class of substituted 5-hydroxy-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-6,10-diones useful as anti-HIV agents. The compounds have the formula: Z═O; R20, R21, R22, R23, R24 and R25 independently are hydrogen, C1-C8 alkyl, (C6-C14)aryl-(C1-C8)alkyl, C6-C14 aryl, or alkoxy; the stereochemistry of an asymmetric carbon represented by * shows R- or S-configuration, or a mixture thereof; RX is hydrogen; R14 is hydrogen or optionally substituted lower alkyl; R3 is hydrogen; R1 is hydrogen or lower alkyl; R is halogen; and m is 1, 2 or 3; or a pharmaceutically acceptable salt thereof.
摘要:
The present invention is directed to a substituted 2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2 -a]pyrido[1,2-d]pyrazine-5,7-dione useful as an anti-HIV agent, which has the formula: as well as pharmaceutically acceptable salts thereof, compostions thereof, and methods of use thereof.
摘要:
The present invention is to provide a novel compound (I) shown below, having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. (wherein Z1 is NR4; R1 is hydrogen or lower alkyl; X is a single bond, a hetero atom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylene in which the hetero atom group may intervene; R2 is optionally substituted aryl; R3 is hydrogen, a halogen, hydroxy, optionally substituted lower alkyl etc; and R4 and Z2 part taken together forms a ring, to form a polycyclic compound, including e.g., a tricyclic or tetracyclic compound.
摘要翻译:本发明提供下述新型化合物(I),具有抗病毒活性,特别是HIV整合酶抑制活性,以及含有该化合物(I)的药物,特别是抗HIV药物,以及方法和 中间体。 (其中Z 1为NR 4; R 1为氢或低级烷基; X为单键,选自O,S,SO,SO 2和NH的杂原子基团,或杂原子基团可插入的低级亚烷基或低级亚烯基) R2是任选取代的芳基; R 3是氢,卤素,羟基,任选取代的低级烷基等;和R 4和Z 2部分一起形成环,形成多环化合物,包括例如三环或四环化合物。